CY1808A - Treatment of prostatic carcinoma with 17beta-n-monosubstituted-carbamoyl-4-aza-5alpha-androst-1-en-3-ones - Google Patents

Treatment of prostatic carcinoma with 17beta-n-monosubstituted-carbamoyl-4-aza-5alpha-androst-1-en-3-ones

Info

Publication number
CY1808A
CY1808A CY180895A CY180895A CY1808A CY 1808 A CY1808 A CY 1808A CY 180895 A CY180895 A CY 180895A CY 180895 A CY180895 A CY 180895A CY 1808 A CY1808 A CY 1808A
Authority
CY
Cyprus
Prior art keywords
5alpha
17beta
androst
monosubstituted
aza
Prior art date
Application number
CY180895A
Other languages
English (en)
Original Assignee
Merck & Co Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Merck & Co Inc filed Critical Merck & Co Inc
Publication of CY1808A publication Critical patent/CY1808A/xx

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/58—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids containing heterocyclic rings, e.g. danazol, stanozolol, pancuronium or digitogenin

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Steroid Compounds (AREA)
CY180895A 1987-04-03 1995-09-08 Treatment of prostatic carcinoma with 17beta-n-monosubstituted-carbamoyl-4-aza-5alpha-androst-1-en-3-ones CY1808A (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US3480887A 1987-04-03 1987-04-03

Publications (1)

Publication Number Publication Date
CY1808A true CY1808A (en) 1995-09-08

Family

ID=21878742

Family Applications (1)

Application Number Title Priority Date Filing Date
CY180895A CY1808A (en) 1987-04-03 1995-09-08 Treatment of prostatic carcinoma with 17beta-n-monosubstituted-carbamoyl-4-aza-5alpha-androst-1-en-3-ones

Country Status (5)

Country Link
EP (1) EP0285383B1 (fr)
CA (1) CA1302276C (fr)
CY (1) CY1808A (fr)
DE (1) DE3888378T2 (fr)
HK (1) HK116594A (fr)

Families Citing this family (35)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE3838716A1 (de) * 1988-11-15 1990-05-17 Kanoldt Arzneimittel Gmbh Arzneimittelzubereitung aus esterderivaten des hecogenins und dessen verwendung zur behandlung von benigner prostatahyperplasie
US5372996A (en) * 1989-03-10 1994-12-13 Endorecherche, Inc. Method of treatment of androgen-related diseases
US5364847A (en) * 1989-03-10 1994-11-15 Endorecherche Inhibitors of sex steroid biosynthesis and methods for their production and use
US5595985A (en) 1989-03-10 1997-01-21 Endorecherche Inc. Combination therapy for prophylaxis and/or treatment of benign prostatic hyperplasia
ATE230994T1 (de) * 1989-07-07 2003-02-15 Endorech Inc Methode zur behandlung androgenbedingter krankheiten
AU5856090A (en) * 1989-07-07 1991-02-06 Endorecherche Inc. Androgen derivatives for use in the inhibition of sex steroid activity
DE69034148T2 (de) * 1989-07-07 2005-06-30 Endorecherche Inc., Ste-Foy Kombinationstherapie zur Prophylaxe und/oder Behandlung von gutartiger prostatischer Hyperplasie
US5300294A (en) * 1990-06-27 1994-04-05 Smithkline Beecham Corporation Method of treating prostatic adenocarcinoma
US5304562A (en) * 1991-10-09 1994-04-19 Ciba-Geigy Corporation 17β-substituted Aza-androstane derivatives
CA2084799C (fr) 1991-12-17 2003-01-28 Glenn J. Gormley Methode de prevention du carcinome prostatique a l'aide de 17 beta-n-monosubstitue-carbamyl-4-aza-5 alpha-androst-1 -en-3-ones
WO1993013124A1 (fr) * 1991-12-20 1993-07-08 Glaxo Inc. Inhibiteurs de la 5-alpha-testosterone reductase
US5994362A (en) * 1992-03-11 1999-11-30 Merck & Co., Inc. Method of treatment for prostatic cancer
UA35589C2 (uk) * 1992-05-21 2001-04-16 Андорешерш Інк. ІНГІБІТОРИ ТЕСТОСТЕРОН 5-<font face="Symbol">a</font>-РЕДУКТАЗИ, ФАРМАЦЕВТИЧНА КОМПОЗИЦІЯ ТА СПОСІБ ІНГІБУВАННЯ АКТИВНОСТІ ТЕСТОСТЕРОН 5-<font face="Symbol">a</font>-РЕДУКТАЗИ
US5302589A (en) * 1992-08-07 1994-04-12 Glaxo, Inc. Heterocyclic inhibitors of 5-α-testosterone reductase
HU212459B (en) * 1992-10-02 1996-06-28 Richter Gedeon Vegyeszet Process for producing new 17-beta-substituted 4-aza-androstane-derivatives and pharmaceutical compositions containing them
US5468860A (en) * 1992-11-19 1995-11-21 Merck & Co., Inc. New finasteride processes
PT674521E (pt) * 1992-12-18 2001-10-31 Merck & Co Inc Metedo para o tratamento da prostatite cronica com 17beta-n-carbamoil monossubstituido-4-aza-5alfa-androst-1-en-3-onas
WO1994022900A1 (fr) * 1993-04-02 1994-10-13 Ciba-Geigy Ag AZA-ANDROSTANE-17β-CARBOXAMIDES
TW408127B (en) * 1993-09-17 2000-10-11 Glaxo Inc Androstenones
TW369521B (en) * 1993-09-17 1999-09-11 Smithkline Beecham Corp Androstenone derivative
US5547957A (en) 1993-10-15 1996-08-20 Merck & Co., Inc. Method of treating androgenic alopecia with 5-α reductase inhibitors
BR9407866A (pt) 1993-10-21 1996-10-29 Merck & Co Inc Composto processos para inibiçao de 5 -redufase ou isoenzimas da mesma paratratamento de condiçoes de acne vulgar alopécia androgènica hirsutismo feminino hiperplasia prostática benigna prostatite e para o tratamento e/ou prevençao do cancer da próstata para interrupçao e reversao de alopécia androgènica e promoçao do crescimento de cabelo em um mamifero e para inibiçao de conversao biossintética da testosterona para di-hidro- testosterona em um mamifero e composiçao farmacèutica
US5637310A (en) * 1993-12-20 1997-06-10 Smithkline Beecham Corporation Method of treating prostatic adenocarcinoma
US5817818A (en) * 1994-09-16 1998-10-06 Glaxo Wellcome Inc. Androstenones
US5541322A (en) * 1994-10-14 1996-07-30 Glaxo Wellcome Inc. Synthesis of 6-azaandrostenones
US5656613A (en) * 1995-01-04 1997-08-12 Merck & Co., Inc. Treatment of hyperandrogenic conditions
US6177404B1 (en) 1996-10-15 2001-01-23 Merck & Co., Inc. Conjugates useful in the treatment of benign prostatic hyperplasia
US6093722A (en) * 1997-02-26 2000-07-25 Sankyo Company, Limited Method for treating prostate cancer
US5998427A (en) * 1998-05-14 1999-12-07 Glaxo Wellcome Inc. Androstenones
US6268377B1 (en) * 1998-09-28 2001-07-31 Merck & Co., Inc. Method for treating androgen-related conditions
US6645974B2 (en) * 2001-07-31 2003-11-11 Merck & Co., Inc. Androgen receptor modulators and methods for use thereof
MXPA04010408A (es) 2002-04-24 2005-02-17 Boehringer Ingelheim Pharma Combinacion farmaceutica para el tratamiento de hiperplasia prostatica benigna o para la prevencion a largo plazo de la retencion urinaria aguda.
US20060019989A1 (en) * 2004-07-21 2006-01-26 Steiner Mitchell S Compositions comprising 5-alpha reductase inhibitors and SERMs and methods of use thereof
WO2023101256A1 (fr) * 2021-12-03 2023-06-08 주식회사 팜어스바이오사이언스 Inhibiteur de 5-alpha-réductase, sel pharmaceutiquement acceptable de celui-ci et utilisation associée
KR102829242B1 (ko) * 2021-12-03 2025-07-07 주식회사 팜어스바이오사이언스 5-알파-환원효소 억제제, 그의 약학적으로 허용 가능한 염 및 그 용도

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU527030B2 (en) * 1978-04-13 1983-02-10 Merck & Co., Inc. 4-aza-17-substituted-5a-androstan-3-ones
NZ211145A (en) * 1984-02-27 1988-10-28 Merck & Co Inc 4-aza-5-alpha-androst-1-en-3-ones and pharmaceutical compositions

Also Published As

Publication number Publication date
EP0285383A2 (fr) 1988-10-05
CA1302276C (fr) 1992-06-02
DE3888378D1 (de) 1994-04-21
EP0285383A3 (en) 1990-09-12
HK116594A (en) 1994-11-04
EP0285383B1 (fr) 1994-03-16
DE3888378T2 (de) 1994-09-29

Similar Documents

Publication Publication Date Title
EP0285383A3 (en) Treatment of prostatic carcinoma with 17beta-n-monosubstituted-carbamoyl-4-aza-5alpha-androst-1-en-3-ones
GB2231265B (en) Therapeutic use of serotonin-antagonists
EP0263645A3 (en) Catheters and methods of using such catheters
EP0588379A3 (en) Treatment of wrinkling
GB2208155B (en) Water treatment assembly
GB2196453B (en) Treatment of floating point numbers
ZA859008B (en) The treatment of tumors in mammals
GB8704532D0 (en) Treatment of froth
GB8719128D0 (en) Treatment of gas
GB2203645B (en) Improvements in the treatment of hair
GB8428722D0 (en) Treatment of pipelines
GB8715914D0 (en) Treatment of cerabral disorders
GB8722529D0 (en) Treatment of burns
SG128894G (en) Treatment of prostatic carcinoma with 17 beta-N-monosubstituted-carbamoyl-4-aza-5 alpha-androst-1-en-3-ones
GB8521996D0 (en) Treatment of structure
GB8500292D0 (en) Treatment of babesiosis
GB8723765D0 (en) Treatment of water
GB8715317D0 (en) Treatment of medium
GB8603461D0 (en) Treatment of stitchware
ZA856034B (en) Treatment of cancer
GB8702688D0 (en) Treatment of gases
ZA887700B (en) Treatment of water
CS886587A1 (en) Treatment of water
GB8704172D0 (en) Treatment of wool
GB8401863D0 (en) Treatment of bromidrosis